SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Oncotarget. 2017;8(38):64440-64448.

Additional K-ras mutation analysis and Plectin-1 staining improve the diagnostic accuracy of pancreatic solid mass in EUS-guided fine needle aspiration.

, , , , , , ,

제1저자 박주경, 백우현 · 교신저자 류지곤

소속 (5)
  1. Department of Medicine, Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  2. Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  3. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  4. Department of Internal Medicine, Myongji Hospital, Goyang, Korea.
  5. Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND One of the major genetic alterations in pancreatic ductal adenocarcinoma (PDAC) is the point mutation of K-ras gene. Plectin-1 was also recently identified as PDAC specific biomarker. The aim of this study was to investigate the improvement of diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) by using additional K-ras mutation analysis and Plectin-1 staining in patients with pancreatic mass.

METHODS A total of 85 study patients with pancreatic mass underwent EUS-FNA and the final diagnoses were as follows; PDACs: 70 patients, pancreas neuroendocrine tumor: 4, metastasis to pancreas: 5, autoimmune pancreatitis: 3, chronic pancreatitis: 1, tuberculous lymphadenitis: 1, pseudocyst: 1.

RESULTS Sensitivity, specificity and accuracy of pathologic diagnosis in EUS-FNA specimen were 81%, 80% and 79% accordingly. When we combine K-ras gene mutation analysis with histological assessment, we could get the following results for sensitivity, specificity and accuracy; cytology and K-ras mutation analysis: 93%, 87%, and 92%, cytology, K-ras mutation analysis, and Plectin-1 staining: 96%, 93%, and 95%.

CONCLUSIONS Triple combinations of the techniques; cytology, K-ras gene mutation analysis, Plectin-1 staining could increase accuracy in diagnosis of PDACs. Further investigation of using minimal specimens from EUS-FNA may give us insight to understand the biological behavior of PDAC.

Keywords

K-rasPlectin-1endoscopic ultrasoundpancreatic ductal adenocarcinoma

Figures

Figure 1
Figure 1 Plectin-1 immunostaining of endoscopic ultrasound-guided fine needle aspiration specimens PDAC, pancreatic ductal adenocarcinoma.
Figure 2
Figure 2 Kaplan-Meier overall survival (OS) curve of patients with pancreatic ductal adenocarcinoma according to KRAS mutation status KRAS mutation was not significantly associated with median overall survival (18.1 vs. 8.1 months, p = 0.1).
Figure 3
Figure 3 Kaplan-Meier overall survival (OS) curve of patients with pancreatic ductal adenomcarcinoma according to number of KRAS mutation There was no statistically significant differences about number of mutation in median OS (wild-type KRAS vs 1 KRAS mutation vs 2 KRAS mutation: Figure 3, 8.1 vs 20.4 vs 14.3 months, p = 0.2).
Figure 4
Figure 4 Schematic flow chart of study design

그림 출처: PubMed Central 공개 논문 (PMC5610015)

Conflict of interest statement

CONFLICTs OF INTEREST The authors declare no conflicts of interest.

그 밖의 정보
출판 형태
Journal Article
저널
Oncotarget · eISSN 1949-2553
전자 출판
2017-03-11
참고문헌
32편